- Home
- ATOS vs HURA Comparison
ATOS vs HURA Comparison
Compare ATOS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- HURA
- Stock Information
- Founded
- ATOS 2009
- HURA 2009
- Country
- ATOS United States
- HURA United States
- Employees
- ATOS N/A
- HURA N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- HURA
- Sector
- ATOS Health Care
- HURA
- Exchange
- ATOS Nasdaq
- HURA Nasdaq
- Market Cap
- ATOS 130.5M
- HURA 131.8M
- IPO Year
- ATOS 2012
- HURA N/A
- Fundamental
- Price
- ATOS $1.00
- HURA $2.41
- Analyst Decision
- ATOS Strong Buy
- HURA Strong Buy
- Analyst Count
- ATOS 3
- HURA 2
- Target Price
- ATOS $6.25
- HURA $11.50
- AVG Volume (30 Days)
- ATOS 1.3M
- HURA 196.4K
- Earning Date
- ATOS 11-11-2025
- HURA 11-13-2025
- Dividend Yield
- ATOS N/A
- HURA N/A
- EPS Growth
- ATOS N/A
- HURA N/A
- EPS
- ATOS N/A
- HURA N/A
- Revenue
- ATOS N/A
- HURA N/A
- Revenue This Year
- ATOS N/A
- HURA N/A
- Revenue Next Year
- ATOS N/A
- HURA N/A
- P/E Ratio
- ATOS N/A
- HURA N/A
- Revenue Growth
- ATOS N/A
- HURA N/A
- 52 Week Low
- ATOS $0.55
- HURA $1.80
- 52 Week High
- ATOS $1.66
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- ATOS 60.15
- HURA 41.31
- Support Level
- ATOS $0.86
- HURA $2.37
- Resistance Level
- ATOS $1.29
- HURA $2.65
- Average True Range (ATR)
- ATOS 0.08
- HURA 0.12
- MACD
- ATOS 0.01
- HURA -0.00
- Stochastic Oscillator
- ATOS 43.16
- HURA 4.07
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.